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Mild traumatic brain injuries (mTBI) have been associated with long-term cognitive
deficits relating to trauma-induced neurodegeneration. These long-term deficits include
impaired memory and attention, changes in executive function, emotional instability, and
sensorimotor deficits. Furthermore, individuals with concussions show a high co-morbidity
with a host of psychiatric illnesses (e.g., depression, anxiety, addiction) and dementia.
The neurological damage seen in mTBI patients is the result of the impact forces and
mechanical injury, followed by a delayed neuroimmune response that can last hours, days,
and even months after the injury. As part of the neuroimmune response, a cascade of
pro- and anti-inflammatory cytokines are released and can be detected at the site of injury
as well as subcortical, and often contralateral, regions. It has been suggested that the
delayed neuroinflammatory response to concussions is more damaging then the initial
impact itself. However, evidence exists for favorable consequences of cytokine production
following traumatic brain injuries as well. In some cases, treatments that reduce the
inflammatory response will also hinder the brain’s intrinsic repair mechanisms. At present,
there is no evidence-based pharmacological treatment for concussions in humans. The
ability to treat concussions with drug therapy requires an in-depth understanding of the
pathophysiological and neuroinflammatory changes that accompany concussive injuries.
The use of neurotrophic factors [e.g., nerve growth factor (NGF)] and anti-inflammatory
agents as an adjunct for the management of post-concussion symptomology will be
explored in this review.
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INTRODUCTION
The awareness of the consequences that arise frommild traumatic
brain injuries (mTBI), commonly referred to as concussions, has
been on the rise and is a “hot topic” in the media, medicine,
and basic research. In light of increasing awareness, a clear
understanding of the immediate and long-term neural pathology
underlying a concussive injury is incomplete thereby preclud-
ing both proper assessment and suitable treatment strategies.
Because of this, the current review paper will examine the patho-
physiological and neuroinflammatory changes that accompany
concussive injuries with the hope of improving assessment and
treatment to curtail the myriad of neurological and psychological
consequences associated with a concussion.
No single definition of concussion (used interchangeably with
mTBI) is accepted across all medical or research disciplines,
though a number of definitions are available (Comper et al.,
2005). In 2001, the first International Symposium on Concussion
in Sport was organized (Aubry et al., 2002) and a viable defini-
tion to describe concussive injuries was offered by the Concussion
in Sport Group. Their definition of a concussion was as fol-
lows: “a complex pathophysiological process affecting the brain,
induced by traumatic biomechanical forces” (Cantu et al., 2006).
The definition was further expanded upon to include the follow-
ing: “temporary impairment of neurological function that heals
by itself over time, and that neuroimaging normally shows no
gross structural changes to the brain as the result of the condition”
(Anderson et al., 2006). Because this definition was maintained
after the 3rd International Conference on Concussion in Sport
held in Zurich (McCrory et al., 2009), it will be followed for the
purpose of this paper noting that the group provided an update
and recommended that the terms concussion and mTBI refer to
different injury constructs and should not be used interchange-
ably (McCrory et al., 2009).
Traumatic biomechanical forces can occur as a result of direct
(to the head) or indirect (to the body) impact (e.g., sports, work-
place accidents), rapid acceleration or deceleration (e.g., motor
vehicle accidents), or intense changes in pressure (e.g., blast expo-
sure). Currently, there is no universally accepted set of symptoms
required to be present in order for a patient to be diagnosed with
a concussion. Rather, there is a wide range of telltale symptoms
that may occur as a consequence of a concussion, which include
headache, nausea, vomiting, dizziness, fatigue, abnormal sleep-
ing patterns, drowsiness, and more (Randolph et al., 2009; Ledic
et al., 2012; Slobounov et al., 2012). The pursuit for a compre-
hensive set of defining symptoms remains to be an area of intense
investigation.
The prevalence of concussions has dramatically increased over
the past decade. This could be due to increased awareness and
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recognition of symptoms as well as improvements in diagnostic
tests and tools, increased survival rates in vehicular accidents and
blast victims, as well as the adoption of more liberal concussion
criteria. In the general population, there are a reported 545 trau-
matic brain injury (TBI) cases per 10,000 people. Of these, 88% of
cases were determined to be concussions (Andersson et al., 2003;
Bazarian et al., 2005). While it is estimated that 25–42% of peo-
ple who suffer concussions do not report them, concussions still
account for a large proportion of documented hospitalizations
and impose a 1–2 billion dollar burden on the United States annu-
ally (Feinstein and Rapoport, 2000; Goldberg et al., 2007). With
such persuasive evidence that concussions are becoming a silent
epidemic, it is surprising that there is no effective concussion
management system in place.
With an increasing awareness of the deficits produced by con-
cussion, there is an increasing demand for readily available treat-
ments. This has provided the impetus for researchers to explore
not only the signs and symptoms but also the neural pathological
mechanisms and long-term outcomes associated with concus-
sions. Over the past decade there have been numerous guidelines
recommended in an attempt to grade concussions and provide
return to play or return to work strategies (Cantu and Register-
Mihalik, 2011; Laker, 2011). Along with the rising awareness of
the overt signs and symptoms of concussions, there have been
momentous advancements in the tools used to properly diag-
nose concussions (McCullough and Jarvik, 2011). One inherent
problem with diagnosing concussions, however, is that present-
ing symptoms are dependent on personal factors such as age,
gender, and history of traumatic brain injuries (Andersson et al.,
2003; Field et al., 2003). To further complicate matters, patients,
especially athletes, are often reluctant to report any symptoms
at all (McCrea et al., 2004; Kutcher et al., 2010). Initial evalua-
tions performed on suspected concussed patients involve a review
of the patient’s history of head injuries followed by an array
of cognitive and behavioral tests in order to make appropriate
diagnoses (Putukian, 2011; Scorza et al., 2012). Because there
may be changes in neurological function, even in the absence
of behavioral abnormalities (Gosselin et al., 2010), there has
been a move toward advanced imaging and biomarker-based
approaches (Davis et al., 2009; Difiori and Giza, 2010; Jeter et al.,
2012). The ability to accurately diagnose concussions has pro-
gressed with the use of: postural correlates, MRI, fMRI, EEG, and
biomarkers in conjunction with behavioral and neuropsycholog-
ical tests (Inglese et al., 2005; Bazarian et al., 2007; Pulsipher
et al., 2011; Slobounov et al., 2012). These objective neuroimaging
and biomarker-based approaches have addressed the issues sur-
rounding the subjectivity of strictly behavioral and self-reported
symptoms allowing for more precise detection of neurobiological
alterations associated with concussions.
NEUROPATHOPHYSIOLOGY OF CONCUSSIONS
Concussions are the result of biomechanical forces that result in
rapid acceleration and decelerations of the brain often leading to
functional impairments in the absence of overt structural dam-
age (Fineman et al., 2000; Gurkoff et al., 2006; Prins et al., 2010).
The metabolic cascade following this type of injury has been
studied extensively in animal models as well as humans (Giza
and Hovda, 2001; Barkhoudarian et al., 2011; Giza and Difiori,
2011). Animal models, such as controlled cortical impact (CCI),
weight drop, fluid percussion, vacuum deformation, and inertial
acceleration have been used considerably to study concussions
and advance our understanding of the neural pathology of brain
injuries (Giza and Difiori, 2011; O’Connor et al., 2011). Based
on an assessment of this work, rotational forces seem to be a
prerequisite for producing the diffuse damage in the brain that
underlies the signs and symptoms associated with a concussion
(Ibrahim et al., 2010). Strong rotational forces cause stretching
and shearing of axonal and cell membranes (i.e., diffuse dam-
age), which leads to an unchecked flux of ions through formerly
regulated channels and membranes (Farkas et al., 2006). As a
consequence of ionic disequilibrium, an indiscriminate release
of excitatory neurotransmitters occurs, instigating a widespread,
and potentially excitotoxic, neuronal depolarization (Katayama
et al., 1990; Kawamata et al., 1992). Furthermore, axonal stretch-
ing facilitates the opening of voltage-dependent K+ channels
causing an abnormal efflux, and ultimately extracellular accu-
mulation of K+ (Takahashi et al., 1981; Katayama et al., 1990).
In attempt to restore ionic equilibrium, adenosine triphosphate
(ATP)-dependent Na+/K+ pumps work in overdrive, necessitat-
ing increased glucose metabolism, which in turn leads to fur-
ther metabolic dysfunction (Yoshino et al., 1991; Andersen and
Marmarou, 1992). This trauma-induced state of hyperglycoly-
sis occurs within minutes and can persist for hours depending
on the type and severity of brain injury (Yoshino et al., 1991).
Hyperglycolysis leads to the overproduction of lactate, which
causes another wave of downstream consequences, ultimately
disrupting neuronal functioning (Kalimo et al., 1981; Gardiner
et al., 1982). To further complicate matters, over-activation of
N-methyl-D-aspartate (NMDA) receptors via hyper-release of
glutamate causes a large influx of Ca2+ that accumulates in the
mitochondria, hindering glucose metabolism leading to impair-
ments in ATP production (Xiong et al., 1997; Babikian et al.,
2012). This acute state of hyperglycolysis subsides shortly after
the injury and is followed by a prolonged state of hypoglycol-
ysis and reduced cerebral blood flow (Martin et al., 1997). The
resulting mismatch in glucose supply vs. demand following a
concussion is thought to produce some of the immediate post-
concussive symptoms and leave the brain vulnerable to secondary
injuries (Giza andHovda, 2001). For a detailed review on the neu-
rometabolic cascade following a concussion, see Giza and Hovda
(2001).
Despite the initial metabolic cascade caused by mechanical
forces, much of the damage suffered from a concussion has been
attributed to the delayed progression of secondary biochemi-
cal events ultimately leading to neuronal dysfunction and, in
some cases, cell death. Understanding these delayed secondary
events following concussions is crucial for the development of
appropriate treatment strategies.
INFLAMMATORY RESPONSE TO CONCUSSIONS
Initially, it was believed that the brain was incapable of marshal-
ing an inflammatory response to combat infection or disease due
to the selective permeability of the blood–brain barrier (BBB).
However, it is now well established that neuroinflammation can
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occur independently of changes in BBB permeability and is com-
monly seen in response to almost all neurological disorders,
including concussions (Csuka et al., 1999, 2000; Fassbender et al.,
2000; Morganti-Kossmann et al., 2001; Gentleman et al., 2004;
Werner and Engelhard, 2007; Ramlackhansingh et al., 2011; Yu
et al., 2011; Kabadi et al., 2012). Interestingly, the permeabil-
ity of the BBB appears to be altered following events such as
combat injury or infection that provoke inflammatory responses
(Cortez et al., 1989; Fukuda et al., 1995; Csuka et al., 1999;
Morganti-Kossmann et al., 1999). Within the central nervous sys-
tem (CNS), the inflammatory response involves the recruitment
of neutrophils and monocytes to the site of injury in an attempt
to aid the injured tissue via the secretion of cytokines and other
signaling molecules (Wang and Feuerstein, 2000; Szmydynger-
Chodobska et al., 2012). In addition to the recruitment of
neutrophils and monocytes, the brain also possesses native cells
capable of organizing an inflammatory response themselves.
Microglia and astrocytes, for example, express inflammatory
mediators and secrete inflammatory cytokines locally (Singh
et al., 2011; Galic et al., 2012). Glial fibrillary acidic protein
(GFAP) expression is widely used as an estimate of astrocyte acti-
vation and has recently been considered as a characteristic marker
in brain-injured patients (Schiff et al., 2012). It has been shown
that patients who have suffered multiple traumatic injuries, with
no history of brain injury, show control levels of GFAP expres-
sion, while patients with a history of brain injury show increased
GFAP expression as a function of the severity of brain injury (Vos
et al., 2010; Yu et al., 2011; Metting et al., 2012; Zurek and Fedora,
2012). Activation of astrocytes and microglia, as evidenced by
protracted GFAP expression, results in the production and secre-
tion of inflammatory cytokines (Csuka et al., 2000; Davalos et al.,
2005). The injured brain, as is the case following a concussion,
undeniably produces an inflammatory response (Holmin et al.,
1998). However, the role of the inflammatory response following
CNS injury remains unclear. On the one hand, prolonged expo-
sure to inflammatory cytokines is ultimately harmful, shifting the
intrinsic neuroprotective efforts of the immune response to the
detrimental effects of neuroinflammation (Barone and Parsons,
2000; Bermpohl et al., 2007; Kumar and Loane, 2012). On the
other, it has been suggested that neuroinflammation contributes
to the neuroprotective regenerating efforts of the brain and in
its absence the cumulative damage is increased following injury
(Ziebell and Morganti-Kossmann, 2010; Khuman et al., 2011).
Here we review the neuroinflammatory response to TBI with a
focus on the beneficial and detrimental effects of inflammation
following a concussion.
INTERLEUKIN-1 (IL-1)
Following the mechanical injury suffered by concussed patients,
there is an acute cytokine response thought to represent, in part,
the neuroprotective defense mechanisms of the brain (Scherbel
et al., 1999). IL-1, a family of 11 cytokines known for their reg-
ulation of inflammatory responses, has been shown to increase
rapidly in both human and rodent cases of mild to severe TBI
(Woodroofe et al., 1991; Fan et al., 1995; Winter et al., 2002).
Within this cytokine superfamily, IL-1α and IL-1β convey a pro-
inflammatory response that aids in the defense against infection
or injury. In rodent models of concussion, IL-1α and IL-1β are
up regulated within hours following injury (Taupin et al., 1993;
Shojo et al., 2010; Dalgard et al., 2012). IL-1α shows an acute spike
following a concussion, while IL-1β shows a much more grad-
ual increase that is thought to represent a portion of the delayed
cytokine response to CNS injury (Holmin et al., 1997). IL-1β lev-
els remain elevated for days following experimental concussions
(Dalgard et al., 2012) and show significantly higher levels rela-
tive to other pro-inflammatory cytokines (Yu et al., 2011). The
elevation in IL-1β levels seen after brain injury appears to be
conditional on the severity of the trauma. As such, it has been
shown that experimental injuries leading to contusions, mimick-
ing a more potent TBI than a concussion, produce more IL-1β
mRNA expression in tissues surrounding the contusion, which
lasts up to 6 days following the onset of injury (Holmin et al.,
1997).
The rise in IL-1β following a concussion precedes the secretion
of ciliary neurotrophic factor (CNTF) and nerve growth factor
(NGF), both of which promote the growth and survival of neu-
rons and defend against the instigation of apoptotic pathways
(Gadient et al., 1990; Dekosky et al., 1996; Herx et al., 2000).
These data suggest that IL-1β provides neuroprotection following
brain injury and therefore might be considered part of the regen-
erative process. Paradoxically, others have shown that chronic
inhibition of IL-1β for up to 1 week following a CCI-induced
mild/moderate TBI reduces cerebral edema and tissue loss while
improving the cognitive outcome by modifying the inflamma-
tory response (Clausen et al., 2009, 2011). These data suggest that
prolonged exposure to IL-1β may be associated with neurotoxic
effects following a concussion.
Given that IL-1β is capable of stimulating the release of other
proinflammatory cytokines, such as tumor necrosis factor-alpha
(TNF-α), it is not surprising the IL-1β inhibition results in
an atypical inflammatory response following fluid percussion
injuries (Woodroofe et al., 1991; Fan et al., 1995). The IL-1β-
dependent hypersecretion of other cytokines may produce a toxic
inflammatory environment for neurons surrounding the site of
injury. Therefore, interrupting IL-1β immediately following the
endogenous secretion of neurotrophic factors might prove to be
effective in concussion management. However, what remains to
be understood is how changes in the severity of brain injury
(mild to moderate to severe TBI) alter the expression of IL-β and
thus mediate downstream cytokine responses. More studies are
required to better characterize the contribution of IL-1β to the
inflammatory mechanisms following a concussion and ascertain
an injury severity-specific temporal profile of IL-1 secretion.
TUMOR NECROSIS FACTOR-α (TNF-α)
Like the IL-1 family of cytokines, TNF-α shows a rapid response
to experimental brain injury and is considered to be an early
mediator of CNS damage (Shojo et al., 2010). Following experi-
mental TBIs, ranging from a mild closed head injury to a more
severe lateral fluid percussion injury, TNF-α rises rapidly and
peaks within hours, returning to normal levels within 24 h of
the injury (Taupin et al., 1993; Shohami et al., 1994; Fan et al.,
1996; Knoblach et al., 1999; Bermpohl et al., 2007; Yang et al.,
2010; Khuman et al., 2011; Dalgard et al., 2012). Similar to IL-1β,
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TNF-α appears to play both neuroprotective and neurotoxic roles
following brain injury (Ziebell and Morganti-Kossmann, 2010).
TNF-α has two known receptors expressed in the CNS: the p55
TNF receptor (TNFR1) and the p75 TNF receptor (TNFR2).
Binding of TNF-α to TNFR1 signals for fibroblast growth,
endothelial cell activation/adhesion and apoptosis possibly via
NF-κB activation (Perry et al., 2001). Binding of TNF-α to TNFR2
appears to be involved in signaling pro-inflammatory responses
as well as enhancing TNFR1-mediated apoptosis (Perry et al.,
2001). It has been suggested that differential binding of TNF-α
to these receptors may explain the differences between its early
detrimental and delayed beneficial properties following concus-
sion or more severe cases of TBI (Arnett et al., 2001). Activation
of TNFR1 signaling pathways is associated with the pathologi-
cal effects of TNF-α while activation of TNFR2 is thought to be
neuroprotective (Kolesnick andGolde, 1994; Sullivan et al., 1999).
Acutely, TNF-α alters the permeability of the BBB, a well-
characterized physiological consequence of concussions (Ramilo
et al., 1990; Kim et al., 1992; Tanno et al., 1992; Habgood
et al., 2007). Appropriate alterations to BBB permeability may
be necessary to regulate the infiltration of blood-born defense
mechanisms following a brain injury (Tanno et al., 1992). For
example, mice lacking complete functional TNF-α signaling show
greater tissue damage, increased BBB permeability, and increased
recovery times following both moderate and severe CCI injuries
(Scherbel et al., 1999; Sullivan et al., 1999), suggesting that TNF-α
is necessary for normal recovery. However, inhibiting TNF-α
transcription and bioactivity pharmacologically following a mild
closed head injury has been shown to improve neurological out-
come and motor function recovery, normalize BBB permeability
and decrease edema size, suggesting inhibition of TNF-α activ-
ity facilitates recovery (Shohami et al., 1996, 1997). Paradoxically,
TNF-α null mice show an early advantage in neurological func-
tion after CCI which is lost over time (Scherbel et al., 1999)
suggesting that TNF-α signaling may be neurotoxic in the acute
stages of TBI. In conjunction with IL-1, TNF-α stimulates the
release of NGF from astrocytes, which may explain some of its
neuroprotective effects (Gadient et al., 1990; Knoblach and Faden,
1998). It is also possible that TNF-α promotes proliferation of
neurons by acting in the subventricular zone (Wu et al., 2000) or
through the induction of NFκ-B expression and subsequent acti-
vation of anti-apoptotic pathways (Cortez et al., 1989; Shohami
et al., 1999). It appears that central blockade of TNF-α follow-
ing a concussion may prove to be beneficial, while prolonged
antagonism could be detrimental.
It is unclear how levels of TNF-α differ as a function of the
severity of brain injury. It has been shown that a concussion does
in fact cause an increase in TNF-α secretion (Shojo et al., 2010);
however, it is uncertain how the increase in TNF-α differs between
a concussion and a more severe brain injury. Furthermore, it has
been shown that TNF-α acts synergistically with other proin-
flammatory cytokines (Chao et al., 1995a; Allan and Rothwell,
2001); therefore, a consideration of these types of interactions
is also necessary to fully understand the TNF-α contribution to
the inflammatory response following a concussion. To address
the issue of treating concussions using TNF-α inhibitors, further
experiments will be required to supplement our understanding
of the time course of toxicity, the signaling pathways important
for recovery, and how the severity of injury dictates the extent of
TNF-α secretion.
INTERLEUKIN-6 (IL-6)
TNF-α, through modulation of the NF-κB pathway, is a potent
stimulator of IL-6 expression (Vanden Berghe et al., 2000). IL-6
acts as both a pro- and anti-inflammatory cytokine (Lenzlinger
et al., 2001) and is considered to be a key regulator during the
acute phase of the inflammatory response to infections and tissue
damage (Kopf et al., 1994). IL-6 has been shown to increase in
experimental models of both mild (Shohami et al., 1994; Holmin
et al., 1997) and moderate/severe (Woodroofe et al., 1991; Taupin
et al., 1993) TBI in rodents and has been detected at high lev-
els for weeks following severe human brain injuries (Kossmann
et al., 1995). In mice lacking IL-6, experimental cortical freeze
injuries or cytotoxic brain injuries result in increased oxida-
tive stress, decreased cell survival, and lengthened recovery times
compared to WT mice, suggesting that in the absence of IL-6,
the brain’s intrinsic repair mechanisms are deficient (Penkowa
et al., 2000, 2003). These data compliment a series of both human
brain injury cases and in vitro studies, whereby IL-6 secretion
leads to elevated production of NGF in astrocytes and suppresses
the production of both TNF-α and IL-1β (Kushima et al., 1992;
Kossmann et al., 1996; Ley et al., 2011). In addition, IL-6 defi-
cient mice exposed to a closed cortical impact, mimicking a mild
TBI, show exaggerated behavioral abnormalities and increased
expression of IL-1β 1 h following injury (Ley et al., 2011).
Overexpression of the IL-6 gene, on the other hand, resulted
in shortened recovery times, a reduction in genes involved in
the control of oxidative stress and reduction in apoptotic path-
way gene expression following a mild cortical freeze injury in
mice (Quintana et al., 2008). It should be noted, however, that in
this particular model, IL-6 overexpression was selectively astro-
cyte driven (GFAP-IL-6). Furthermore, although this model of
GFAP-IL-6 overexpression produced beneficial effects following
an acute cortical injury, these mice showed spontaneous neu-
roinflammatory responses and developed long-term neurological
dysfunctions (Campbell et al., 1993; Quintana et al., 2008).
It has not yet been established how IL-6 participates in the
secondary neurodegeneration that occurs in concussed patients.
The aforementioned cases propose an association between IL-
6 and a variety of CNS injuries; however, there has yet to be a
study that investigates the relationship between IL-6 and concus-
sion directly. While IL-6 overexpressionmay have neuroprotective
effects in some instances of CNS damage, it would appear that
they are location and time specific. If IL-6 exerts its neuroprotec-
tive effects through modulation of NGF, TNF-α or IL-1β, then
astrocyte driven overexpression, or exogenous administration,
must occur at a time when these factors are still malleable.
TRANSFORMING GROWTH FACTOR-β (TGF-β)
The role of anti-inflammatory cytokines in response to
concussion is very poorly understood. It would seem intu-
itive that anti-inflammatory molecules are secreted to counter-
act the consequences of a propagating inflammatory response.
However, anti-inflammatory cytokines serve opposing roles in
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response to brain injury; some effects are beneficial while oth-
ers are detrimental. One of the earliest discovered functions of
the anti-inflammatory cytokine, TGF-β, was its ability to promote
tissue repair by dampening the inflammatory response (Wahl,
1992). TGF-β expression is induced by the presence of inflam-
matory cytokines and has been shown to form a negative feed-
back loop by suppressing the production of pro-inflammatory
cytokines such as IL-1, IL-6, TNF-α, and IFN-γ (Benveniste
et al., 1995; Chao et al., 1995b). Furthermore, TGF-β can dis-
rupt the recruitment of leukocytes to the site of injury through
modulation of chemotactic signals (Wahl, 1994). This negative
feedback system ensures that the host is protected from prolif-
erating inflammatory attacks. However, the beneficial effects of
TGF-β seem to be dependent on its temporal release and concen-
tration. Excessive expression of TGF-β, for example, has not only
been shown to hinder the intrinsic repairmechanisms of the brain
but also confer a predisposition for the development of serious
infections (Wahl, 1992; Lowrance et al., 1994).
Given that TGF-β is secreted in response to inflammatory
cytokines, it is of no surprise that expression of TGF-β peaks
within 24 h after TBI in human cases (Csuka et al., 1999;
Morganti-Kossmann et al., 1999) as well as animal models of
mild TBI (Csuka et al., 1999; Morganti-Kossmann et al., 1999; Yu
et al., 2011). It has been suggested that TGF-β confers potential
short-term beneficial effects following clinical and experimental
TBIs by down regulating the inflammatory response; however,
in the long-term TGF-β may be detrimental and increase the
risk of developing other neurological disorders (Wahl, 1992;
Lenzlinger et al., 2001). When considering the therapeutic poten-
tial of TGF-β following brain injury, it should be noted that only
local administration has been shown to promote tissue repair,
while systemic administration results in an immunosuppressive
reaction (Mustoe et al., 1987). Additionally, dosages must be
titrated carefully given the enhanced vulnerability to infection
caused by excessive TGF-β concentrations (Wahl, 1992; Lowrance
et al., 1994). More studies need to be conducted to characterize
the effects of TGF-β treatment following concussion particu-
larly addressing the issues of timing, concentration, and route of
administration in order to isolate its beneficial effects.
INTERLEUKIN-10 (IL-10)
In addition to TGF-β, the other predominant anti-inflammatory
molecule involved in the response to brain injury is IL-10.
Increased IL-10 secretion from astrocytes and microglia has been
shown following a range of CNS injuries from concussions to
severe TBI (Csuka et al., 1999; Maskin et al., 2001; Wu et al., 2005;
Yu et al., 2011). Presently, the role of IL-10 following concussion
is controversial. It has been suggested that IL-10 is neuroprotec-
tive as it decreases levels of reactive oxygenated species (Csuka
et al., 1999), decreases the expression of several pro-inflammatory
cytokines including IL-1 and TNF-α (Knoblach and Faden, 1998;
Csuka et al., 1999), and helps suppress further activation of
microglia and astrocytes (Kremlev and Palmer, 2005). It should
be noted however that the beneficial effects of IL-10 adminis-
tration are transient and circumstantial. These beneficial effects
appear to be dose- and site-specific, requiring pre-treatment
in order to confer protection, while the type of injury model
also seems to influence the use of IL-10 as a benefactor. In
severe human TBI cases, reports have not shown any correla-
tion between IL-10 levels and recovery time (Csuka et al., 1999),
while others report that IL-10 expression is associated with neg-
ative outcomes (Shiozaki et al., 2005; Kirchhoff et al., 2008).
Similarly, animal models of brain injury show mixed results. One
model demonstrated marked improvements in recovery from a
TBI following IL-10 treatment (Knoblach and Faden, 1998), while
others fail to report any beneficial effects of IL-10 treatment fol-
lowing hypoxia-ischemic brain injury (Lyng et al., 2005). With
such a wide variety of the type and severity of traumatic brain
injuries used in both clinical and experimental research, it is
difficult to gauge the role of IL-10 in response to concussion.
Consequently, the contributions of IL-10 to the inflammatory
response following mild TBI remain to be determined.
TREATMENT
As the awareness of and willingness to report concussive symp-
toms increases in society, the need for effective treatment
strategies has gained momentum. Considerable evidence demon-
strating the cumulative and potentially fatal effects of experienc-
ing a concussion while still symptomatic from a previous injury
(second impact syndrome, SIS) has prioritized treatments that
will shorten recovery times and minimize susceptibility (Deford
et al., 2002; Tavazzi et al., 2007; Prins et al., 2010). To date, there is
no effective treatment for a concussion. Concussion management
thus far has focused on prevention (e.g., helmets, rule changes)
and the philosophy of “rest, rest, rest” allowing symptoms to
subside naturally before clearance to normal activity is approved.
Recently the use of anti-inflammatory drugs for the treatment
of concussion has been closely examined. As it is now becom-
ing more evident that lingering neuroinflammatory mechanisms
contribute to the secondary damage following a concussion, the
use of non-steroidal anti-inflammatory drugs (NSAIDs) seems
to be an attractive option. That being said, there is evidence to
suggest NSAIDs may not be the best pharmacotherapy for man-
aging the neurobiological factors underlying concussive injuries.
It has been shown that chronic treatment with ibuprofen, one of
the most commonly used NSAIDs, worsens the cognitive alter-
ations in rodents exposed to an experimental TBI (Browne et al.,
2006). Other NSAIDs, such as minocycline, are capable of reduc-
ing apoptotic damage in several forms of CNS injury, such as
spinal cord injury, but do not show any beneficial effects when
examining recovery times from mild TBI (Stirling et al., 2004;
Maier et al., 2005). Taken together, these data demonstrate that
preventing an inflammatory response to a concussion is not a
viable treatment, despite its effectiveness in treating other trau-
matic injuries occurring in the CNS. Furthermore, this evidence
suggests that the concussed brain presents a unique inflamma-
tory signature as opposed to a general inflammatory response that
occurs following any CNS injury.
Other drugs designed to target specific pro-inflammatory
cytokines have also been used as potential treatment therapies for
TBI patients. HU-211, for example, is used as a selective TNF-α
inhibitor (Biegon and Joseph, 1995). TNF-α seems to have the
highest cytotoxic properties as compared with other cytokines,
and therefore HU-211 may be a viable treatment candidate.
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As such, administration of HU-211 within 24 h of a mild closed
head TBI was shown to decrease cell death within the hippocam-
pus and facilitate recovery of motor function in rodents (Shohami
et al., 1997). Unfortunately, human trials showed no differences
between the drug and placebo group and HU-211 was removed
from clinical trials (Maas et al., 2006).
Very recently, there has been particular attention paid to
endogenous anti-inflammatory molecules, such as Nesfatin-1.
Nesfatin-1 is a peptide secreted from hypothalamic centers in
response to inflammation (Bonnet et al., 2009). Administration
of Nesfatin-1 has been shown to decrease inflammation and
decrease the expression of apoptotic markers within hours of a
TBI (Tang et al., 2012). Specifically, Nesfatin-1 has been shown
to reduce the expression of pro-inflammatory cytokines such as
TNF-α, IL-1β and IL-6, as well as decrease caspase-3 activity fol-
lowing TBI (Tang et al., 2012). The isolation and administration
of endogenous anti-inflammatory molecules, such as Nesfatin-1,
provides hope for the use of anti-inflammatory drugs in the treat-
ment of concussive injuries. However, it should be noted that the
beneficial effects of Nesfatin-1 administration were preceded by
5 consecutive days of peripheral administration and there was
no time-response relationship (Tang et al., 2012). Therefore, it
remains unclear whether acute, post-concussive treatment with
Nesfatin-1 would provide any lasting protection or if a continuous
presence of Nesfatin-1 is required as would result from preventa-
tive dosing. Further studies are needed to investigate the potential
therapeutic effects of peripherally administered endogenous anti-
inflammatory agents following concussions.
The failures of NSAIDs and other anti-inflammatory agents
in mitigating post-concussive damage highlight the necessity for
customized drugs designed for a very specific use. One issue that
must be addressed in order to develop relevant treatment strate-
gies for concussed patients is the timing when treatments are
most effective. There seems to be a narrow window of opportu-
nity wherein certain drugs can penetrate the BBB (Habgood et al.,
2007) and gain access to the site of injury following a concussion.
Drug administration must not occur too soon as to interfere with
the neuroprotective effects of inflammation, or too late, when
the damage is too great to overcome. For example, a drug that
permits the acute secretion of IL-1β and IL-6 but antagonizes
any long-term accumulation of these cytokines could potentially
harness the early advantages described in the literature while
blocking the long-term detrimental effects. In addition, damp-
ening the acute secretion of TNF-α and TGF-β may prove to be
beneficial whereas prolonged interruption may lead to deleterious
outcomes. Therefore, drug therapies that can strike the balance
between acute and delayed actions of cytokines may prove to be
appropriate targets for pharmacological treatment of concussion.
One issue that remains unclear, however, is whether or not the
dueling role of inflammatory cytokines are the consequence of
concentration gradients or synergistic effects in the presence of
other cytokines secreted at different time points.
CONCLUSION
The awareness and recognition of concussive brain injuries is
on the rise in large part due to improvements in diagnos-
tic/assessment techniques, increased survival rates from accidents
and media attention. With a large number of available defini-
tions, there is no doubt that the term “concussion” will be used
in common parlance to describe an array of cognitive symptoms
that result from biomechanical forces to the brain. Nevertheless,
the search for a viable concussion treatment is higher now than
ever before. A further understanding of the detrimental neu-
robiological effects caused by a concussion will be required in
order to develop appropriate treatment strategies. The acute
metabolic cascade following a concussion has been character-
ized in detail over the past several decades (Giza and Hovda,
2001; Barkhoudarian et al., 2011). Unfortunately, targeting the
metabolic cascade has failed to produce viable treatment options
given its rapid onset and the temporal reality of reaching a con-
cussed patient in time to stop this cascade from progressing.
Therefore, treatment strategies focused onmanaging the neuroin-
flammatory responses to concussion may prove to be more tan-
gible targets, as it is hypothesized these delayed secondary effects
may be the primary source of long-term neural damage. There
are promising data to suggest that manipulating neuroinflamma-
tion can be used as treatment strategies to manage the long-term
deficits produced by a concussive injury. However, the use of gen-
eral anti-inflammatory drugs will not serve as a “magic bullet”
for this silent epidemic. Rather, it seems that a tailored array of
pro- and anti-inflammatory compounds given at particular tem-
poral intervals will likely be implemented given the complexity of
the inflammatory response to concussion. Treatments will likely
differ based on severity of brain injury, age of the patient, and
previous history of brain injury. Furthermore, treatment strate-
gies require close attention be paid to when a patient consults a
medical professional after brain injury given the fluctuations of
inflammatory profiles over time following a concussion.
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